新型双药涂层球囊血管成形术与普通球囊血管成形术治疗股腘动脉病变的结果对比
该研究评估了新型药物涂层球囊(Elutax)治疗股腘动脉病变的24个月安全性和有效性。2019年1月至2020年1月连续纳入53例患者(53条肢体)接受Elutax治疗(A组),与2017年1月至2018年1月接受普通球囊血管成形术(POBA)的71例患者(71条肢体,B组)进行非同期对照比较。结果显示Elutax组24个月再狭窄/再闭塞率低于POBA组(9.4% vs. 25.3%,P=0.034),一期通畅率更高(88.2% vs. 71.5%,log rank P=0.03)。
要点
- Elutax组24个月再狭窄/再闭塞率为9.4%,低于POBA组的25.3%(P=0.034)。
- Elutax组24个月一期通畅率为88.2%,高于POBA组的71.5%(log rank P=0.03)。
- 两组技术成功率均为100%,A组补救支架置入率16.9%(9/53),B组为22.5%(16/71)。
核心结论
- 紫杉醇+右旋糖酐药物涂层球囊血管成形术在治疗股腘动脉慢性病变中安全有效。
- 作者经验显示Elutax相比POBA具有更优的一期通畅率。
研究设计与样本
- 研究为单中心非同期对照研究,A组为2019年1月至2020年1月连续接受Elutax药物涂层球囊治疗的53例患者(53条肢体)。
- B组为2017年1月至2018年1月接受普通球囊血管成形术(POBA)的71例患者(71条肢体)。
- 两组术前均接受临床检查、超声评估和CT血管造影以明确基线和病变特征。
主要发现
- 两组技术成功率均为100%,A组补救支架置入率为16.9%(9/53),B组为22.5%(16/71)。
- A组24个月再狭窄/再闭塞率为9.4%,B组为25.3%(CI 95% 0.01-0.30,P=0.034)。
- A组24个月一期通畅率为88.2%,B组为71.5%(log rank P=0.03)。
- A组24个月临床驱动的靶病变血运重建率为7.5%,B组为18.3%。
- A组随访期保肢率为94.9%,B组为92.1%;所有小截肢均发生在表现为慢性肢体威胁性缺血(CLTI)的肢体。
临床怎么用
- 作者认为紫杉醇+右旋糖酐药物涂层球囊血管成形术在股腘动脉慢性病变的管理中安全有效。
- 作者经验显示Elutax相比POBA具有更优的一期通畅率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The study aimed to assess the 24-month safety and effectiveness of a new generation drug-coated balloon (DCB) (Elutax; AR Baltic Medical, Vilnius Lithuania-also marketed as Emperor in some European countries; Aachen Resonance, Germany, and AB Medica, Italy) for the treatment of patients with femoropopliteal lesions. METHODS: From January 2019 to January 2020, DCB angioplasties using Elutax were performed on 53 consecutive patients (53 limbs) with femoropopliteal lesions (group A) and compared with a noncontemporary control group (group B) consisting of 71 patients (71 limbs) treated with plain old balloon angioplasty (POBA) between January 2017 and January 2018. Before performing the angioplasty, both groups underwent clinical examination, ultrasound evaluation, and computed tomography angiography to delineate subject clinical and baseline lesion characteristics. Primary end point was primary patency rate at 24 months. Secondary end points included clinically driven target lesion revascularization (CD-TLR), overall survival and limb salvage rates. RESULTS: In both groups technical success rate was 100% with bailout stenting performed in 16.9% (9/53) of lesions in group A, while stenting was necessary in 22.5% of lesions (16/71) in group B. Patients treated with Elutax exhibited lower 24-month restenosis/reocclusion rate and improved primary patency compared to those treated with POBA (restenosis/reocclusion rate: 9.4% vs. 25.3%, CI 95% 0.01-0.30, P = 0.034; primary patency: 88.2% vs. 71.5%, log rank P = 0.03). Twenty-four-month CD-TLR rate was 7.5% for DCB versus 18.3% for POBA. No device or procedure-related deaths occurred, and no 30-day mortality was observed in either group. During the follow-up period, the limb salvage rate was 94.9% for A group and 92.1% for B group. All minor amputations occurred in limbs presented with chronic limb threatening ischemia (CLTI). Overall survival was 91.7% for group A and 89.4% for group B. CONCLUSIONS: Paclitaxel + Dextran DCB angioplasty proved safe and effective in managing chronic lesions of femoropopliteal arteries. Our experience has shown superior primary patency rate for Elutax when compared to POBA.
引用
- Sallustro M, Peluso A, Turchino D, et al. Results of New Dual-Drug Coated Balloon Angioplasty versus POBA for Femoropopliteal Lesions. Ann Vasc Surg. 2022. PMID: 36374662. doi:10.1016/j.avsg.2022.09.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。